← Back
Data updated: Sep 20, 2026
HANDA ONCOL
Pharma Pharmaceuticals
HANDA ONCOL is a pharmaceutical company with 1 FDA-approved products.
2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules
HANDA ONCOL's Key Drugs
HANDA ONCOL's core commercial portfolio centers on OMCAZIO — its most strategically important drugs approved in the last 15 years.
HANDA ONCOL's Recent FDA Approvals
HANDA ONCOL secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
HANDA ONCOL's Therapeutic Areas
Disease areas where HANDA ONCOL has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
HANDA ONCOL Pipeline Snapshot
Active clinical trials for HANDA ONCOL across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OMCAZIO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-09-03
- Latest
- 2026-09-03
- Applications
- 1